585 completed, 579 unknown, 250 recruiting, 166 terminated. 618 Phase 2, 347 Not applicable, 324 Phase 1, 201 Phase 3, 58 Phase 4.
Follow Hepatocellular Carcinoma: new trials by email Literature Review of Hepatocellular Carcinoma trials Research Report on Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | West China Hospital | 60 | 2026-12-01 | 2026-10-08 |
| A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 690 | 2026-11-01 | 2026-10-29 |
| Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC) | Not yet recruiting | Assiut University | 294 | 2026-11-01 | 2026-10-29 | |
| GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer GLP1-RA (semaglutide) - Pancreatic Cancer, Colorectal Cancer | Early Phase 1 | Recruiting | University of Arizona | 30 | 2026-10-10 | 2026-09-18 |
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer Lung Cancer Non-small Cell, Colorectal Cancer | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2000 | 2026-10-01 | 2026-10-19 | |
| Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma | Not yet recruiting | University of Oklahoma | 2000 | 2026-10-01 | 2026-07-29 | |
| Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL) - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | Not applicable | Not yet recruiting | University of California, San Francisco | 64 | 2026-10-01 | 2026-10-06 |
| Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention - Hepatocellular Carcinoma, Pancreas Cancer | Not applicable | Not yet recruiting | City of Hope Medical Center | 70 | 2026-10-01 | 2026-08-20 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 492 | 2026-10-01 | 2026-09-23 |
| Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma Arm 1 cemiplimab, Arm 2 cemiplimab and fianlimab - Hepatocellular Carcinoma | Phase 1 | Withdrawn | Virginia Commonwealth University | 2026-10-01 | 2026-09-14 | |
| PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 40 | 2026-09-30 | 2026-09-18 |
| Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anhui Provincial Hospital | 60 | 2026-09-16 | 2026-09-21 |
| Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) Hepatocellular Carcinoma, Liver Cirrhosis | Not yet recruiting | D'Or Institute for Research and Education | 300 | 2026-09-15 | 2026-08-14 | |
| Patients With Hepatocellular Carcinoma (HCC) Fecal microbiota transplantation performed via colonoscopy., Simulated Colonoscopy With Placebo Capsules in Addition to Standard Treatment - Hepatocellular Carcinoma, Hepatocellular Cancer | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 52 | 2026-09-01 | 2026-07-21 |
| ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 600 | 2026-09-01 | 2026-09-10 |
| Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC Systemic therapy, Local therapy - Hepatocellular Carcinoma | Not yet recruiting | Shanghai Zhongshan Hospital | 400 | 2026-09-01 | 2026-09-02 | |
| 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors 68Ga-SorB PET/CT - Melanoma (Skin Cancer), Hepatocellular Carcinoma | Not applicable | Recruiting | Peking University Third Hospital | 50 | 2026-08-13 | 2026-10-15 |
| Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 2 | Withdrawn | University of Miami | 2026-08-01 | 2026-06-15 |
Showing 20 of 1846. Sign in to see all of them.
Carcinoma, Hepatocellular (1846) · Liver Neoplasms (231) · Colorectal Neoplasms (67) · Cholangiocarcinoma (66) · Carcinoma, Non-Small-Cell Lung (63) · Stomach Neoplasms (59) · Carcinoma, Renal Cell (58) · Fibrosis (55) · Liver Cirrhosis (55) · Neoplasms (55) · Melanoma (48) · Pancreatic Neoplasms (39) · Recurrence (38) · Hepatitis B (35) · Neoplasm Metastasis (34)
Neoplasms by Histologic Type (1842) · Neoplasms by Site (1842) · Neoplasms, Glandular and Epithelial (1842) · Adenocarcinoma (1840) · Digestive System Diseases (1839) · Digestive System Neoplasms (1837) · Carcinoma (1825) · Liver Diseases (1817) · Neoplasms (1791) · Liver Neoplasms (1615) · Pathological Conditions, Signs and Symptoms (232) · Pathologic Processes (217) · Gastrointestinal Diseases (118) · Gastrointestinal Neoplasms (105) · Urogenital Diseases (100)
Sorafenib (129) · lenvatinib (94) · Bevacizumab (81) · Nivolumab (53) · pembrolizumab (49) · atezolizumab (48) · sintilimab (43) · durvalumab (42) · Radiosurgery (37) · Fluorouracil (35) · Oxaliplatin (32) · apatinib (29) · Radiotherapy (28) · camrelizumab (28) · Radiofrequency Ablation (27)
Sun Yat-sen University (134) · Seoul National University Hospital (39) · Eastern Hepatobiliary Surgery Hospital (35) · Shanghai Zhongshan Hospital (34) · Fudan University (33) · Guangxi Medical University (29) · National Taiwan University Hospital (23) · Zhejiang University (22) · Assistance Publique - Hôpitaux de Paris (20) · National Cancer Institute (NCI) (19) · Chinese University of Hong Kong (17) · Zhongda Hospital (17) · AstraZeneca (16) · Asan Medical Center (15) · Kaohsiung Medical University Chung-Ho Memorial Hospital (15)
China (690) · United States (413) · South Korea (168) · Taiwan (149) · France (136) · Italy (101) · Spain (84) · Germany (70) · Canada (65) · Hong Kong (64) · Japan (59) · United Kingdom (53) · Singapore (46) · Belgium (44) · Australia (33)
Ming Shi, MD (19) · Tim F Greten, M.D. (10) · Jeong Min Lee, MD (9) · Shen Feng, MD (6) · Gao-Jun Teng, M.D. (5) · Jung-Hwan Yoon, M.D., Ph.D. (5) · Ming Zhao, M.D. & Ph.D. (5) · David Hsieh, MD (4) · Feng Duan, MD (4)
PMID 12049862, PMID 11981766, PMID 12540794, PMID 19192962, PMID 36852452, PMID 12091661, PMID 18650514, PMID 29628281, PMID 14667750, PMID 19095497, PMID 21374666, PMID 27932229, PMID 29433850, PMID 29875066, PMID 34143971, PMID 16250051, PMID 16495695, PMID 16557381, PMID 19766639, PMID 19908093, PMID 20590903, PMID 20839057, PMID 23099728, PMID 23269991, PMID 23547075, PMID 25747273, PMID 27704266, PMID 28130846, PMID 28434648, PMID 29366520, PMID 29471013, PMID 29543938, PMID 29972759, PMID 30251931, PMID 31070690, PMID 31401903, PMID 31790344, PMID 32107609, PMID 32278280, PMID 32418078, PMID 32557715, PMID 32716739, PMID 32817068, PMID 33188713, PMID 33531690, PMID 33538338, PMID 33822328, PMID 33856599, PMID 34795131, PMID 35247922
2023 (9), 2018 (8), 2015 (5), 2016 (5), 2019 (5), P30CA060553 (4), 2014 (3), 2025 (3), 2005 (2), 2017 (2), N01CN00042 (2), P30CA012197 (2), P30CA014089 (2), P30CA015083 (2), 2008 (1)